Dizal (jiangsu) Pharmaceutical Co., Ltd.

Other

Dizal Pharmaceutical Co., Limited

Zhengtao Li

Xiaolin Zhang

Zhenfan Yang

Honchung Tsui

Wei Zhu

Jiabing Wang

Xiang Chen

Qingbei Zeng

Hao Zou

Changmao Shen

Wei Zhong

Rumin Wang

Wengeng Liu

Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.

ErbB/BTK inhibitors

Disclosed are quinazoline compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds which are useful in treating diseases associated ErbBs. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.

ERBB receptor inhibitors

Disclosed are compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.

ErbB receptor inhibitors

Growing community of inventors

Shanghai, China

Zhengtao Li